Alnylam Pharmaceuticals Inc’s recently made public that its Officer Fitzgerald Kevin Joseph acquired Company’s shares for reported $5.45 million on Nov 17 ’25. In the deal valued at $449.00 per share,12,128 shares were bought.
Then, Greenstreet Yvonne sold 15,650 shares, generating $7,100,322 in total proceeds. Upon selling the shares at $453.69, the Chief Executive Officer now owns 65,409 shares.
Before that, Greenstreet Yvonne sold 10,000 shares. Alnylam Pharmaceuticals Inc shares valued at $4,512,682 were divested by the Chief Executive Officer at a price of $451.27 per share. As a result of the transaction, Greenstreet Yvonne now holds 65,409 shares, worth roughly $30.24 million.
Wolfe Research upgraded its Alnylam Pharmaceuticals Inc [ALNY] rating to a Peer perform from a an Underperform in a research note published recently. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who increased its forecast for the stock in early August from “a Perform” to “an Outperform”. Truist started covering the stock on July 21, 2025. It rated ALNY as “a Buy”.
Price Performance Review of ALNY
On Tuesday, Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] saw its stock jump 0.38% to $462.3. Over the last five days, the stock has gained 2.29%. Alnylam Pharmaceuticals Inc shares have risen nearly 79.25% since the year began. Nevertheless, the stocks have risen 96.46% over the past one year. While a 52-week high of $495.55 was reached on 10/20/25, a 52-week low of $205.87 was recorded on 04/09/25.
Levels Of Support And Resistance For ALNY Stock
The 24-hour chart illustrates a support level at 456.01, which if violated will result in even more drops to 449.72. On the upside, there is a resistance level at 468.85. A further resistance level may holdings at 475.40.
How much short interest is there in Alnylam Pharmaceuticals Inc?
A steep rise in short interest was recorded in Alnylam Pharmaceuticals Inc stocks on 2025-10-31, growing by 0.26 million shares to a total of 3.77 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 3.51 million shares. There was a rise of 6.94%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 31, 2025 when Redburn Atlantic began covering the stock and recommended ‘”a Buy”‘ rating along with a $353 price target.
